Scavengers of reactive oxygen species, paracalcitol, RhoA, and Rac-1 inhibitors and tacrolimus inhibit angiotensin II-induced actions on glomerular permeability

American Journal of Physiology - Renal Physiology

Volumn 305, Issue 3, 2013, Pages

  Axelsson, Josefin ^a   Rippe, Anna ^a   Sverrisson, Kristinn ^a   Rippe, Bengt ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Capillary permeability; Ficoll; Glomerular sieving coefficient; Microalbuminuria; Two pore model

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; ANGIOTENSIN II; DIMETHYLTHIOUREA; GUANOSINE TRIPHOSPHATASE; PARICALCITOL; PROSTACYCLIN; RAC1 PROTEIN; REACTIVE OXYGEN METABOLITE; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; TACROLIMUS; TEMPOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; GLOMERULAR FILTRATION BARRIER; MALE; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; URINALYSIS;

EID: 84881013153     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00154.2013     Document Type: Article

References (45)

1. Arikan H, Koc M, Cakalagaoglu F, Eren Z, Segal MS, Tuglular S, Ozener C, Akoglu E. Tacrolimus rescue therapy in resistant or relapsing cases of primary glomerulonephritis. J Nephrol 21: 713-721, 2008.
2. Asgeirsson D, Venturoli D, Rippe B, Rippe C. Increased glomerular permeability to negatively charged Ficoll relative to neutral Ficoll in rats. Am J Physiol Renal Physiol 291: F1083-F1089, 2006.
3. Axelsson J, Rippe A, Venturoli D, Swärd P, Rippe B. Effects of early endotoxemia and dextran-induced anaphylaxis on the size selectivity of the glomerular filtration barrier in rats. Am J Physiol Renal Physiol 296: F242-F248, 2009.
4. Axelsson J, Rippe A, Rippe B. Acute hyperglycemia induces rapid, reversible increases in glomerular permeability in nondiabetic rats. Am J Physiol Renal Physiol 298: F1306-F1312, 2010.
5. Axelsson J, Rippe A, Rippe B. Transient and sustained increases in glomerular permeability following ANP infusion in rats. Am J Physiol Renal Physiol 300: F24-F30, 2011.
6. Axelsson J, Rippe A, Öberg C, Rippe B. Rapid, dynamic changes in glomerular permeability to macromolecules during angiotensin II (ANG II) infusion in rats. Am J Physiol Renal Physiol 303: F790-F799, 2012.
7. Bentzer P, Grande PO. Low-dose prostacyclin restores an increased protein permeability after trauma in cat skeletal muscle. J Trauma 56: 385-392, 2004.
8. Bentzer P, Venturoli D, Carlsson O, Grande PO. Low-dose prostacyclin improves cortical perfusion following experimental brain injury in the rat. J Neurotrauma 20: 447-461, 2003.
9. Cattran DC, Greenwood C, Ritchie S, Bernstein K, Churchill DN, Clark WF, Morrin PA, Lavoie S. A controlled trial of cyclosporine in patients with progressive membranous nephropathy. Canadian Glomerulonephritis Study Group. Kidney Int 47: 1130-1135, 1995.
10. Charbit M, Gubler MC, Dechaux M, Gagnadoux MF, Grunfeld JP, Niaudet P. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol 22: 57-63, 2007.
11. Chong TJ, Victorino GP. Angiotensin II subtype AT1 and AT2 receptors regulate microvascular hydraulic permeability via cAMP and cGMP. J Surg Res 131: 105-110, 2006.
12. Davies SP, Reddy H, Caivano M, Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105, 2000.
13. de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 376: 1543-1551, 2010.
14. Eckel J, Lavin PJ, Finch EA, Mukerji N, Burch J, Gbadegesin R, Wu G, Bowling B, Byrd A, Hall G, Sparks M, Zhang ZS, Homstad A, Barisoni L, Birbaumer L, Rosenberg P, Winn MP. TRPC6 enhances angiotensin II-induced albuminuria. J Am Soc Nephrol 22: 526-535, 2011.
15. Faul C, Donnelly M, Merscher-Gomez S, Chang YH, Franz S, Delfgaauw J, Chang JM, Choi HY, Campbell KN, Kim K, Reiser J, Mundel P. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14: 931-938, 2008.
16. Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 74: 1394-1402, 2008.
17. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci USA 101: 7618-7623, 2004.
18. Garrido AM, Griendling KK. NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 302: 148-158, 2009.
19. Greiber S, Munzel T, Kastner S, Muller B, Schollmeyer P, Pavenstadt H. NAD(P)H oxidase activity in cultured human podocytes: effects of adenosine triphosphate. Kidney Int 53: 654-663, 1998.
20. Greka A, Mundel P. Balancing calcium signals through TRPC5 and TRPC6 in podocytes. J Am Soc Nephrol 22: 1969-1980, 2011.
21. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994.
22. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med 351: 2715-2729, 2004.
23. Hsu HH, Hoffmann S, Endlich N, Velic A, Schwab A, Weide T, Schlatter E, Pavenstadt H. Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J Mol Med (Berl) 86: 1379-1394, 2008.
24. Komers R, Oyama TT, Beard DR, Tikellis C, Xu B, Lotspeich DF, Anderson S. Rho kinase inhibition protects kidneys from diabetic nephropathy without reducing blood pressure. Kidney Int 79: 432-442, 2011.
25. Komrskova D, Lojek A, Hrbac J, Ciz M. A comparison of chemical systems for luminometric determination of antioxidant capacity towards individual reactive oxygen species. Luminescence 21: 239-244, 2006.
26. Kriz W, Shirato I, Nagata M, Lehir M, Lemley KV. The podocyte's response to stress: the enigma of foot process effacement. Am J Physiol Renal Physiol 304: F333-F347, 2013.
27. Kushiro M, Shikata K, Sugimoto H, Shikata Y, Miyatake N, Wada J, Miyasaka M, Makino H. Therapeutic effects of prostacyclin analog on crescentic glomerulonephritis of rat. Kidney Int 53: 1314-1320, 1998.
28. Lund U, Rippe A, Venturoli D, Tenstad O, Grubb A, Rippe B. Glomerular filtration rate dependence of sieving of albumin and some neutral proteins in rat kidneys. Am J Physiol Renal Physiol 284: F1226-F1234, 2003.
29. McCarthy ET, Sharma M. Indomethacin protects permeability barrier from focal segmental glomerulosclerosis serum. Kidney Int 61: 534-541, 2002.
30. Meyrier A. Treatment of focal segmental glomerulosclerosis. Exp Opin Pharmacother 6: 1539-1549, 2005.
31. Möller CC, Wei C, Altintas MM, Li J, Greka A, Ohse T, Pippin JW, Rastaldi MP, Wawersik S, Schiavi S, Henger A, Kretzler M, Shankand SJ, Reiser J. Induction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol 18: 29-36, 2007.
32. Nijenhuis T, Sloan AJ, Hoenderop JG, Flesche J, van Goor H, Kistler AD, Bakker M, Bindels RJ, de Boer RA, Moller CC, Hamming I, Navis G, Wetzels JF, Berden JH, Reiser J, Faul C, van der Vlag J. Angiotensin II contributes to podocyte injury by increasing TRPC6 expression via an NFAT-mediated positive feedback signaling pathway. Am J Pathol 179: 1719-1732, 2011.
33. Rippe B, Haraldsson B. Transport of macromolecules across microvascular walls. The two-pore theory. Physiol Rev 74: 163-219, 1994.
34. Rippe C, Asgeirsson D, Venturoli D, Rippe A, Rippe B. Effects of glomerular filtration rate on Ficoll sieving coefficients (theta) in rats. Kidney Int 69: 1326-1332, 2006.
35. Sachse A, Wolf G. Angiotensin II-induced reactive oxygen species and the kidney. J Am Soc Nephrol 18: 2439-2446, 2007.
36. Sonneveld R, Ferre S, Hoenderop JG, Dijkman HB, Berden JH, Bindels RJ, Wetzels JF, van der Vlag J, Nijenhuis T. Vitamin D down-regulates TRPC6 expression in podocyte injury and proteinuric glomerular disease. Am J Pathol 182: 1196-1204, 2013.
37. Spindler V, Schlegel N, Waschke J. Role of GTPases in control of microvascular permeability. Cardiovasc Res 87: 243-253, 2010.
38. Tian D, Jacobo SM, Billing D, Rozkalne A, Gage SD, Anagnostou T, Pavenstadt H, Hsu HH, Schlondorff J, Ramos A, Greka A. Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels. Sci Signal 3: ra77, 2010.
39. Waldman M, Austin HA 3rd., Treatment of idiopathic membranous nephropathy. J Am Soc Nephrol 23: 1617-1630, 2012.
40. Wang L, Ellis MJ, Fields TA, Howell DN, Spurney RF. Beneficial effects of the Rho kinase inhibitor Y27632 in murine puromycin aminonucleoside nephrosis. Kidney Blood Press Res 31: 111-121, 2008.
41. Wang L, Ellis MJ, Gomez JA, Eisner W, Fennell W, Howell DN, Ruiz P, Fields TA, Spurney RF. Mechanisms of the proteinuria induced by Rho GTPases. Kidney Int 81: 1075-1085, 2012.
42. Waschke J, Baumgartner W, Adamson RH, Zeng M, Aktories K, Barth H, Wilde C, Curry FE, Drenckhahn D. Requirement of Rac activity for maintenance of capillary endothelial barrier properties. Am J Physiol Heart Circ Physiol 286: H394-H401, 2004.
43. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Ebersviller S, Burchette JL, Pericak Vance MA, Howell DN, Vance JM, Rosenberg PB. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308: 1801-1804, 2005.
44. Yamada M, Sasaki R, Sato N, Suzuki M, Tamura M, Matsushita T, Kurumatani H. Amelioration by beraprost sodium, a prostacyclin analogue, of established renal dysfunction in rat glomerulonephritis model. Eur J Pharmacol 449: 167-176, 2002.
45. Zhu L, Jiang R, Aoudjit L, Jones N, Takano T. Activation of RhoA in podocytes induces focal segmental glomerulosclerosis. J Am Soc Nephrol 22: 1621-1630, 2011.